618,750 Shares in Alumis Inc. (NASDAQ:ALMS) Purchased by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC purchased a new stake in Alumis Inc. (NASDAQ:ALMS) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 618,750 shares of the company’s stock, valued at approximately $8,229,000. Alumis accounts for about 4.9% of Ally Bridge Group NY LLC’s portfolio, making the stock its 7th largest position. Ally Bridge Group NY LLC owned 1.33% of Alumis as of its most recent SEC filing.

Separately, Towerview LLC acquired a new position in shares of Alumis in the second quarter valued at approximately $4,123,000.

Alumis Trading Up 0.9 %

ALMS stock opened at $11.47 on Monday. The business’s 50-day moving average is $12.24. Alumis Inc. has a 52 week low of $10.37 and a 52 week high of $13.53.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($23.10) EPS for the quarter, missing the consensus estimate of ($1.57) by ($21.53). On average, equities analysts predict that Alumis Inc. will post -6.86 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ALMS shares. Leerink Partnrs upgraded shares of Alumis to a “strong-buy” rating in a research report on Tuesday, July 23rd. Guggenheim initiated coverage on shares of Alumis in a report on Tuesday, July 23rd. They issued a “buy” rating and a $32.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a report on Monday, August 19th. Morgan Stanley initiated coverage on Alumis in a report on Tuesday, July 23rd. They issued an “overweight” rating and a $36.00 price objective on the stock. Finally, Leerink Partners assumed coverage on Alumis in a research note on Tuesday, July 23rd. They set an “outperform” rating and a $29.00 target price for the company. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Alumis presently has an average rating of “Buy” and an average price target of $27.50.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.